HUM-MOLGEN events: Understanding Biomarker Expression Using Multiplex Immunofluorescence (mIF) with FFPE Access for Clinical Trials

Who Should Attend?

This webinar will appeal to:

Immunotherapy researchers and developers seeking to implement innovative biomarker strategies in any phase of development, especially clinical trial phases of precision oncology programs.

Anyone involved in conducting biomarker studies for solid tumor indications, including, but not limited to:

Founders/CEOs/CSOs
R&D Managers, Directors
Biomarker Heads, Directors
Principal Scientists
Clinical Scientists
Research Scientists/Associates

What You Will Learn

Join this webinar to learn:

Why multiplex immunofluorescence (mIF) is an important consideration for biomarker strategies in global clinical trials

How streamlined access to formalin-fixed paraffin-embedded (FFPE) tissues combined with mIF and digital image analysis accelerate biomarker identification in clinical trials

How an approach of integrated mIF assays and digital image analysis (DIA) validation is rooted in a fully Good Clinical Laboratory Practice (GCLP) compliant clinical trial environment

Speaker

Thomas Henkel, PhD, Executive Vice President of Science & Innovation, Discovery Life Sciences

Dr. Thomas Henkel currently manages the scientific integration and extension of Discovery’s global tissue biomarker services portfolio. Before joining Discovery, Dr. Henkel was the CEO and co-founder of TARGOS Molecular Pathology GmbH, Kassel, a company focusing on research and development services regarding clinical biomarkers and targeted therapeutics. Targos was established in 2005 and developed into a premium molecular pathology service provider. From 2002 to 2005, he was Head of Biomedical Research at the Klinikum Kassel GmbH, an activity leading to the foundation of TARGOS GmbH. Prior to this, Dr. Henkel was Vice President Research at MediGene AG, Martinsried, which he joined shortly after its foundation in 1995 and led the research programs through an IPO in 2000. From 1993 to 1995 he worked scientifically at Tularik Inc., San Francisco. Dr. Henkel received his scientific education and his diploma in Biology and Biochemistry from the Georg-August- Universität and the Max-Planck Institute for Experimental Medicine in Göttingen. After his graduation he performed scientific work at the Gene Center München, the Hadassah Medical School Jerusalem and the Salk Institute in San Diego. Dr. Henkel holds a PhD in Biochemistry from the Ludwig-Maximilians-Universität München. Dr. Henkel co-authored more than 30 publications, including one of the most cited Annual Reviews in Immunology. He is also the author of 15 patents. Since 2004, Dr. Henkel is a lecturer in Biochemistry at the Universität Kassel. He received business and management training and education in Munich and St. Gallen.